Study to Compare different formulations of AZD3355

Study identifier:D9120C00031

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A double-blind, randomized, cross-over design, phase 1 pharmacodynamic study to investigate the effect of different formulations of AZD3355 for the development of paresthesiae after dosing in healthy subjects

Medical condition

Gastroesophageal Reflux Disease

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD3355

Sex

All

Actual Enrollment

48

Study type

Interventional

Age

18 Years - 45 Years

Date

Study Start Date: 01 Apr 2008
Primary Completion Date: 01 Jun 2008
Study Completion Date: 01 Jun 2008

Study design

Allocation: Randomized
Endpoint Classification: Pharmacokinetics/dynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria